Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.67 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.67 |
| ▸ | DNPH1 | O43598 | 10/20 | 0.63 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.63 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.63 |
| ▸ | LDHA | P00338 | 1/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.63 |
| ▸ | FBP1 | P09467 | 1/20 | 0.63 |
| ▸ | SRC | P12931 | 1/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.63 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.63 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.63 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.63 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071492 | 1.00 | TAS1R3 (0.67) | TAS1R3TAS1R1DNPH1PRKAB2TRPM2 | |
| SCHEMBL15248807 | 1.00 | TAS1R3 (0.67) | TAS1R3TAS1R1DNPH1PRKAB2TRPM2 | |
| SCHEMBL18999736 | 0.93 | NT5E (0.58) | TAS1R3TAS1R1DNPH1PRKAB2TRPM2 | |
| SCHEMBL14946168 | 0.92 | P2RX3 (0.69) | SRCP2RY2P2RY1SMN1; SMN2P2RY11 | |
| SCHEMBL15249230 | 0.85 | DNPH1 (0.73) | TAS1R3TAS1R1DNPH1PRKAB2TRPM2 | |
| SCHEMBL15248804 | 0.85 | TAS1R3 (0.70) | TAS1R3TAS1R1DNPH1PRKAB2TRPM2 | |
| SCHEMBL15071485 | 0.85 | TAS1R3 (0.70) | TAS1R3TAS1R1DNPH1PRKAB2TRPM2 | |
| SCHEMBL14928618 | 0.85 | TAS1R3 (0.70) | TAS1R3TAS1R1DNPH1PRKAB2TRPM2 | |
| SCHEMBL14928636 | 0.85 | DNPH1 (0.73) | TAS1R3TAS1R1DNPH1PRKAB2TRPM2 | |
| SCHEMBL16657537 | 0.85 | CA5A (0.61) | TAS1R3TAS1R1DNPH1PRKAB2TRPM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180125937-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNATX, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9878056-B2 | Modified polynucleotides for the production of cosmetic proteins and peptides | MODERNATX, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2018-01-04 | — | — | US | disclosed |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-28 | — | — | US | disclosed |
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-07 | — | — | US | disclosed |
| US-9828416-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9827332-B2 | Modified polynucleotides for the production of proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9814760-B2 | Modified polynucleotides for the production of biologics and proteins associated with human disease | MODERNATX, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20130253043-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF G-CSF | modeRNA Therapeutics (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130245106-A1 | METHOD OF PRODUCING A PROTEIN OF INTEREST | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245107-A1 | DLIN-MC3-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245104-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST IN A PRIMATE | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244279-A1 | FORMULATION AND DELIVERY OF PLGA MICROSPHERES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244278-A1 | FORMULATION AND DELIVERY OF PLGA MICROSPHERES | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | TAS1R3 2352/4885TAS1R1 2700/4885DNPH1 467/4885 |
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | TAS1R3 4321/4885TAS1R1 4320/4885DNPH1 2509/4885 |
| US-20180125937-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | TAS1R3 4333/4885TAS1R1 4149/4885DNPH1 1229/4885 |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | POLRMT, POLN, PHAX | TAS1R3 4545/4885TAS1R1 4615/4885DNPH1 3443/4885 |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | TAS1R3 4333/4885TAS1R1 4149/4885DNPH1 1229/4885 |
| US-20130237592-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST AT THE SITE OF A CLOT | TIA1, PAIP1, PHAX | TAS1R3 4151/4885TAS1R1 4146/4885DNPH1 3239/4885 |
| US-20170348436-A1 | IN VIVO PRODUCTION OF PROTEINS | MSH2, POLRMT, POLN | TAS1R3 4059/4885TAS1R1 4015/4885DNPH1 2771/4885 |
| US-20130245107-A1 | DLIN-MC3-DMA LIPID NANOPARTICLE DELIVERY OF MODIFIED POLYNUCLEOTIDES | NSUN3, PLIN3, MCOLN3 | TAS1R3 3203/4885TAS1R1 4634/4885DNPH1 2646/4885 |
| US-20130245104-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST IN A PRIMATE | IGF2BP1, PAIP1, PHAX | TAS1R3 4549/4885TAS1R1 4490/4885DNPH1 3115/4885 |
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | TAS1R3 3866/4885TAS1R1 3712/4885DNPH1 2948/4885 |
| US-20130245106-A1 | METHOD OF PRODUCING A PROTEIN OF INTEREST | IGF2BP1, PHAX, IGF2BP2 | TAS1R3 4689/4885TAS1R1 4654/4885DNPH1 3732/4885 |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | MSH2, POLN, MSH6 | TAS1R3 3444/4885TAS1R1 3318/4885DNPH1 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.